MAX-40279 in Subjects With Acute Myelogenous Leukemia (AML)

Status Recruiting

Clinical Trial Summary

This is a dose-escalation phase I trial to evaluate the safety and tolerability of MAX-40279 in subjects with acute myelogenous leukemia(AML).

Clinical Trial Description

The class III receptor tyrosine kinase FMS-related tyrosine kinase 3 (FLT3), is mutated and activated in about 30% of adult patients with AML. The mutations involve either an internal tandem duplication (ITD) (in about 25% of AML patients) or a point mutation in the tyrosine kinase domain (TKD) (in about 7% of patients). Patients with mutations in FLT3, particularly those with ITD mutations, have a worse prognosis, with lower rate of complete remission, and lower overall survival . Thus, inhibition of activated FLT3 kinase by a pharmacologic agent is an attractive therapeutic strategy in AML. The aberrant of fibroblast growth factor receptor (FGFR) might be a major reason fot resistance to targeted therapies, and FGFR inhibitors significantly suppress leukemia development in vivo. MAX-40279 is a dual inhibitor of FLT3 and FGFR. Our goal is to develpe this uqiue dual inhibitor to be a more effective and wider use for AML treatment than the current known FLT3 inhibitors. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03412292
Study type	Interventional
Source	Maxinovel Pty., Ltd.
Contact	Chun Fong, MD
Phone	+61394965000
Email	chun.fong@austin.org.au
Status	Recruiting
Phase	Phase 1
Start date	August 1, 2018
Completion date	December 1, 2022

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00528983` - Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myelogenous Leukemia	Phase 1
Completed	`NCT01221857` - Pilot Study Evaluating Safety & Efficacy of DCBT: NiCord® & UNM CBU to Patients With Hematological Malignancies	Phase 1/Phase 2
Terminated	`NCT01451437` - Study of MK-8242 Alone and in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia (P07649)	Phase 1
Completed	`NCT01885897` - IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT	Phase 1/Phase 2
Recruiting	`NCT05884333` - Cord Blood Transplant in Adults With Blood Cancers	Phase 2
Terminated	`NCT01873495` - Omacetaxine for Consolidation and Maintenance	Phase 2
Terminated	`NCT03600909` - A Study of the Effect of Blood Stem Cell Transplant After Chemotherapy Alone in Patients With Fanconi Anemia	Phase 2
Completed	`NCT00088543` - Thymoglobulin to Prevent Acute Graft vs. Host Disease (GvHD) in Patients With Acute Lymphocytic Leukemia (ALL) or Acute Myelogenous Leukemia (AML) Receiving a Stem Cell Transplant	N/A
Active, not recruiting	`NCT02061800` - CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant	Phase 1/Phase 2
Terminated	`NCT01113502` - Eltrombopag in Elderly Acute Myelogenous Leukemia (AML)	Phase 1/Phase 2
Withdrawn	`NCT00943553` - A Randomized Study of Epigenetic Priming Using Decitabine With Front Line Induction Chemotherapy Compared With Immediate Induction Chemotherapy in Pediatric Acute Myelogenous Leukemia (AML) Subjects	Phase 2
Terminated	`NCT01050764` - Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells	Phase 1/Phase 2
Terminated	`NCT00672152` - A Phase I Study of WT1 Peptides to Induce Anti-Leukemia Immune Responses Following Transplantation	Phase 1
Recruiting	`NCT03260101` - Non-interventional, Long-term Follow-up of Subjects Who Completed ApoGraft-01 Study
Terminated	`NCT02200380` - A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs	Phase 2
Active, not recruiting	`NCT02240537` - Phase I Study of an Oncofetal Antigen Multi-Peptide Immunotherapy in Subjects With Hematologic Cancer	Phase 1
Completed	`NCT01527838` - Single Treatment With FT1050 of an Ex-vivo Modulated Umbilical Cord Blood Unit	Phase 1
Terminated	`NCT00779480` - Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Study of KW-2449 in Acute Myelogenous Leukemia (AML) (Protocol Number: 2449-US-002)	Phase 1
Completed	`NCT01768845` - Unrelated Umbilical Cord Blood (UBC)Transplantation	N/A
Terminated	`NCT01265199` - Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Properties of Oral AT-406 in Combination With Daunorubicin and Cytarabine in Patients With Poor-risk Acute Myelogenous Leukemia (AML)	Phase 1